



# JOURNAL OF CONTROLLED RELEASE

Official journal of the [Controlled Release Society](#), and of the Japan Society of Drug Delivery System

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

●	<b>Description</b>	<b>p.1</b>
●	<b>Audience</b>	<b>p.1</b>
●	<b>Impact Factor</b>	<b>p.1</b>
●	<b>Abstracting and Indexing</b>	<b>p.2</b>
●	<b>Editorial Board</b>	<b>p.2</b>
●	<b>Guide for Authors</b>	<b>p.5</b>



ISSN: 0168-3659

### DESCRIPTION

The *Journal of Controlled Release* (JCR) publishes high-quality research articles in the broad field of delivery science and technology. This includes drug delivery systems and all aspects of formulations, such as physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, *in vivo* testing, and formulation research and development in the disciplines of pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Manuscripts that advance fundamental understanding of principles and/or demonstrate advantages of novel technologies in safety and efficacy over current clinical standards will be given priority. Each issue has the cover story highlighting the significance of a selected article published in the issue. At the end of each quarter, the JCR editors select "The Editors' Choice" from the published research articles.

#### Benefits to authors

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our [Support Center](#)

crslogo.gif

### AUDIENCE

Investigators involved in pharmacy, biomaterials, chemistry, polymer chemistry, several specializations in medicine, agricultural sciences, pharmaceuticals, chemical technology and mechanical engineering.

### IMPACT FACTOR

2016: 7.786 © Thomson Reuters Journal Citation Reports 2017

## ABSTRACTING AND INDEXING

---

BIOSIS  
Chemical Abstracts  
Current Contents/Life Sciences  
MEDLINE®  
International Pharmaceutical Abstracts  
EMBASE  
Polymer Contents  
Science Citation Index  
CAB Abstracts  
Scopus

## EDITORIAL BOARD

---

### **Editor-in-Chief:**

**K. Park**, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907-2091, USA.  
Email: jcr-americas@akinainc.com  
jcr-americas@akinainc.com

### **Associate Editors for the Americas:**

**Y.H. Bae**, Dept. of Pharmaceutics and Pharmaceutical Chemistry, The University of Utah, 421 Wakara Way, Suite 315, Salt Lake City, Utah, UT 84108, USA

**S. Mitragotri**, Dept. of Chemical Engineering, University of California at Santa Barbara, Santa Barbara, California, CA 93106-5080, USA

**S.P. Schwendeman**, Dept. of Pharmaceutical Sciences, University of Michigan, 428 Church Street, Ann Arbor, Michigan, MI 48109, USA

### **Editor for Europe:**

**S.C. De Smedt**, Lab. of Gen. Biochem. & Physical Pharmacy, Universiteit Gent, Ottergemsesteenweg 460, 9000, Gent, Belgium

### **Associate Editors for Europe**

**T. Lammers**, Dept. of Experimental Molecular Imaging, RWTH Aachen University (RWTH), Pauwelsstrasse 30, 52074, Aachen, Germany

**J. Leroux**, Institute of Pharmaceutical Sciences, Eidgenössische Technische Hochschule (ETH) Zürich, Vladimir-Prelog-Weg 1-5/10, 8093, Zürich, Switzerland

**D. Peer**, Laboratory of NanoMedicine, Dept. of Cell Research & Immunology and Dept. of Materials Science & Engineering, Tel Aviv University, Tel Aviv, Israel.

### **Editor for Asia:**

**I.C. Kwon**, Biomedical Research Center, Korea Institute of Science and Technology (KIST), Hwarangro 14gil 5, 02792, Seongbuk-Gu, Seoul, The Republic of Korea

### **Associate Editors for Asia:**

**H. Harashima**, Lab. Mol. Design of Pharmaceutics, Fac. of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, 060-0812, Sapporo, Japan

**A. Kikuchi**, Dept. of Materials Science and Tech., Tokyo University of Science, 6-3-1 Niijuku, Katsushika, 125-8585, Tokyo, Japan

**Y. Oh**, College of Pharmacy, Laboratory of Nano Biodrug Delivery, Seoul National University (SNU), 1 Gwanak-Ro, Gwanak-Gu, 08826, Seoul, The Republic of Korea

### **Review Editor:**

**V. Torchilin**, Pharmaceutical Sciences, Northeastern University, 360 Huntington Ave., Boston, Massachusetts, MA 02115-5000, USA

### **Special Issue Editor:**

**W.E. Hennink**, Dept. of Pharmaceutics, Utrecht Inst. for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, Netherlands

### **Theme Issue Editor:**

**J. Hanes**, The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, Maryland, MD 21231, USA

**Concept Papers Editor:**

**Y.H. Bae**, Dept. of Pharmaceutics and Pharmaceutical Chemistry, The University of Utah, 421 Wakara Way, Suite 315, Salt Lake City, Utah, UT 84108, USA

**Advisor:**

**T. Nagai**, Nagai Foundation Tokyo, 1-27-10-1201, Hon-Komagome, Bunkyo-ku, 113-0021, Tokyo, Japan

**Editorial Board:**

**H Akita**, Chiba, Japan

**C. Allen**, Toronto, Ontario, Canada

**M.J. Alonso**, Santiago de Compostela, Spain

**M. Amiji**, Boston, Massachusetts, USA

**T.L. Bowersock**, Kalamazoo, Michigan, USA

**K. Braeckmans**, Gent, Belgium

**Y. Byun**, Seoul, The Republic of Korea

**P. Caliceti**, Padova, Italy

**X. Chen**, Changchun, China

**P. Couvreur**, Châtenay-Malabry, France

**M. Davies**, Nottingham, UK

**A.J. Domb**, Jerusalem, Israel

**L. Ensign**, Baltimore, Maryland, USA

**T. Etrych**, Prague, Czech Republic

**E. Fattal**, Châtenay-Malabry, France

**M. Foldvari**, Waterloo, Ontario, Canada

**B. Gander**, Zürich, Switzerland

**H. Ghandehari**, Salt Lake City, Utah, USA

**G. Golomb**, Jerusalem, Israel

**D.W. Grainger**, Salt Lake City, Utah, USA

**T. Ishida**, Tokushima, Japan

**T. Jin**, Shanghai, China

**A.T. Jones**, Cardiff, Wales, UK

**A. Kabanov**, Chapel Hill, North Carolina, USA

**K. Kataoka**, Tokyo, Japan

**I.S. Kim**, Seongbuk-Gu, Seoul, The Republic of Korea

**K. Kim**, Seoul, The Republic of Korea

**J. Kopecek**, Salt Lake City, Utah, USA

**G.S. Kwon**, Madison, Wisconsin, USA

**M. Lee**, Yongin, The Republic of Korea

**C.-M. Lehr**, Saarbrücken, Germany

**K.W. Leong**, Columbia, New York, USA

**T. Li**, Lexington, Kentucky, USA

**K. Mäder**, Halle/Saale, Germany

**H. Maeda**, Kumamoto, Japan

**E. Mastrobattista**, Utrecht, Netherlands

**E. Mathiowitz**, Providence, Rhode Island, USA

**O. Merkel**, München, Germany

**A.G. Mikos**, Houston, Texas, USA

**T. Minko**, Piscataway, New Jersey, USA

**S.M. Moghimi**, Durham, UK

**Y. Nagasaki**, Tsukuba, Japan

**N. Nishiyama**, Yokohama, Japan

**H. Okada**, Tokyo, Japan

**T. Okano**, Tokyo, Japan

**D.W. Pack**, Urbana, Illinois, USA

**J.H. Park**, Suwon, The Republic of Korea

**N.A. Peppas**, Austin, Texas, USA

**Y. Perrie**, Glasgow, Scotland, UK

**M. Prausnitz**, Atlanta, Georgia, USA

**S. Pun**, Seattle, Washington, USA

**T. Rades**, Copenhagen, Denmark

**K. Roy**, Atlanta, Georgia, USA

**M.W. Saltzman**, New Haven, Connecticut, USA

**R.M. Schiffelers**, Utrecht, Netherlands

**R.A. Siegel**, Minneapolis, Minnesota, USA

**J. Siepmann**, Lille, France

**X. Sun**, Chengdu, China

**H.-W. Sung**, Hsin-Chu, Taiwan, ROC

**I. Uchegbu**, London, UK  
**A. Urtti**, Helsinki, Finland  
**M.J. Vicent**, Valencia, Spain  
**E. Wagner**, München, Germany  
**C.H. Wang**, Singapore  
**Y. Yeo**, West Lafayette, Indiana, USA  
**Q. Zhang**, Beijing, China  
**Z. Zhong**, Suzhou, Jiangsu Province, China

***Founding Editors:***

**J. Feijen**, Hengelo, Netherlands  
**J. Heller**

## GUIDE FOR AUTHORS

---

### SCOPE OF THE JOURNAL

The *Journal of Controlled Release* (JCR) publishes high-quality research articles in the broad field of delivery science and technology. This includes drug delivery systems and all aspects of formulations, such as physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, *in vivo* testing, and formulation research and development in the disciplines of pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Manuscripts that advance fundamental understanding of principles and/or demonstrate advantages of novel technologies in safety and efficacy over current clinical standards will be given priority. Each issue has the cover story highlighting the significance of a selected article published in the issue. At the end of each quarter, the JCR editors select "The Editors' Choice" from the published research articles. For more information about the types of articles sought by JCR please read the this [editorial](#).

Papers that provide no new concepts or mechanistic insights will not be considered. The Letter of Submission should explain in one paragraph the originality and significance of the submitted work. The manuscript will not be processed without this information.

Please note that figures and tables should be embedded in the text as close as possible to where they are initially cited and for **REVISED PAPERS ONLY it is mandatory to upload separate graphic and table files also as these will be required if your manuscript is accepted for publication.**

### Contact details for submission

Persons considering submitting a 'Review' article are encouraged to send an outline and a CV to the Review Editor.

#### Review Editor

**Prof. V.P. Torchilin**, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Mugar Building, Room 312, 360 Huntington Ave, Boston, MA 02115, USA; e-mail: v.torchilin@neu.edu

### Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

#### Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

#### Manuscript:

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files* (where applicable)

*Supplemental files* (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

## BEFORE YOU BEGIN

### *Ethics in publishing*

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

### *Declaration of interest*

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. [More information](#).

### *Submission declaration and verification*

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [CrossCheck](#).

### *Changes to authorship*

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

### *Article transfer service*

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information](#).

### *Copyright*

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

### *Author rights*

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

*Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### *Funding body agreements and policies*

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

### **Open access**

This journal offers authors a choice in publishing their research:

#### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

#### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our [universal access programs](#).
- No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

#### *Creative Commons Attribution (CC BY)*

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

#### *Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 3500**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

#### *Green open access*

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more](#).

This journal has an embargo period of 12 months.

### *Elsevier Publishing Campus*

The Elsevier Publishing Campus ([www.publishingcampus.com](http://www.publishingcampus.com)) is an online platform offering free lectures, interactive training and professional advice to support you in publishing your research. The College of Skills training offers modules on how to prepare, write and structure your article and explains how editors will look at your paper when it is submitted for publication. Use these resources, and more, to ensure that your submission will be the best that you can make it.

### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

### **Additional information**

The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others, this has been appropriately cited or quoted. An author should not in general publish manuscripts describing essentially the same research in more than one journal of primary publication. Plagiarism in all its forms as well as submission of the same manuscript to more than one journal concurrently constitutes unethical publishing behaviour and are unacceptable. Thus, the Letter of Submission should explain in one paragraph the originality and significance of the submitted work. The manuscript will not be processed without this information.

## **PREPARATION**

### **Peer review**

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of one independent expert reviewer to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

### **Use of wordprocessing software**

It is important that the file be saved in the native format of the wordprocessor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the wordprocessor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). See also the section on Electronic illustrations.

To avoid unnecessary errors you are strongly advised to use the "spell-check" and "grammar-check" functions of your wordprocessor.

### **Article structure**

#### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

#### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

#### *Results*

Results should be clear and concise.



### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### **Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### **Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

### **Graphical abstract**

Authors must supply a graphical abstract at the time the paper is submitted. The abstract should summarize the contents of the paper in a concise, pictorial form designed to capture the attention of a wide readership and for compilation of databases. The graphical abstract is posted online only. Carefully drawn figures that serve to illustrate the theme of the paper are desired. Authors may also provide appropriate text, not exceeding 30 words. The content of the graphical abstract will be typeset and should be kept within an area of 5 cm by 17 cm (189 x 642 pixels), images should have a minimum resolution of 300 dpi and line art should be between 1000dpi and 1200dpi. Authors must supply the graphic separately as an electronic file. For examples of graphical abstracts, please visit the home page of *Journal of Controlled Release* at <http://www.sciencedirect.com/science/journal/01683659>.

### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

### **Abbreviations**

Abbreviations that are unavoidable must be defined at their first use in the manuscript. Ensure consistency of abbreviations throughout the article.

### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### *Formatting of funding sources*

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## **Artwork**

### **Electronic artwork**

#### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Save text in illustrations as "graphics" or enclose the font.
- Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Produce images near to the desired size of the printed version.
- Submit each figure as a separate file.

A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

Regardless of the application used, when your electronic artwork is finalised, please "save as" or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS: Vector drawings. Embed the font or save the text as "graphics".

TIFF: color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

DOC, XLS or PPT: If your electronic artwork is created in any of these Microsoft Office applications please supply "as is".

#### **Please do not:**

- Supply files that are optimised for screen use (like GIF, BMP, PICT, WPG); the resolution is too low;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

#### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

#### *Figure captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

## Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

## References

### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

### *Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

A DOI can be used to cite and link to electronic articles where an article is in-press and full citation details are not yet known, but the article is available online. A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#) and [Zotero](#), as well as [EndNote](#). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/journal-of-controlled-release>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

### Reference formatting

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

### Reference style

**Text:** Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

**List:** Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

### Examples:

Reference to a journal publication:

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, *J. Sci. Commun.* 163 (2010) 51–59.

Reference to a book:

[2] W. Strunk Jr., E.B. White, *The Elements of Style*, fourth ed., Longman, New York, 2000.

Reference to a chapter in an edited book:

[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), *Introduction to the Electronic Age*, E-Publishing Inc., New York, 2009, pp. 281–304.

Reference to a website:

[4] Cancer Research UK, Cancer statistics reports for the UK. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/>, 2003 (accessed 13.03.03).

Reference to a dataset:

[dataset] [5] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oak wilt disease and surrounding forest compositions, *Mendeley Data*, v1, 2015. <https://doi.org/10.17632/xwj98nb39r.1>.

### Journal abbreviations source

Journal names should be abbreviated according to the [List of Title Word Abbreviations](#).

### Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB in total. Any single file should not exceed 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

## **RESEARCH DATA**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. Before submitting your article, you can deposit the relevant datasets to *Mendeley Data*. Please include the DOI of the deposited dataset(s) in your main manuscript file. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. [More information and examples are available](#). Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

### **Interactive plots**

This journal enables you to show an Interactive Plot with your article by simply submitting a data file. [Full instructions](#).



### **Additional information**

Sources of commercial products need not be listed unless unique. Published methods need not be restated but must be referenced. Where the reference is to papers under review or in press, copies should be provided to the Editor to facilitate review. Full chemical names of drugs/polymers/exipients, etc. should be given. Trade names should not be used. Appropriate statistical analysis of data should be provided

The [Declaration of Helsinki](#) as amended in Fortaleza 2013 for humans, and the European Community guidelines as accepted principles for the use of experimental animals, must be adhered to. Therefore, the Journal of Controlled Release will only consider manuscripts that describe experiments that have been carried out under approval of an institutional or local ethics committee. Authors must state in the manuscript that the protocol complies with the particular recommendation and that approval of their protocols was obtained.

Full chemical names of drugs/polymers/exipients, etc. should be given. Trade names should not be used. Appropriate statistical analysis of data should be provided.

## **AFTER ACCEPTANCE**

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

## **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2014 Elsevier | <http://www.elsevier.com>